The effect of PARP and PLK1 dual inhibition on the expression of important protein signaling pathways, DNA damage, and molecular docking scores against MCF-7 and MDA-MB-231 breast cancer cell lines.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Irish Journal of Medical Science

• Publication date

  2025-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11845-025-04127-8PMID 41233610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer

  2023cited by this paper
• DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review

  2023cited by this paper
• Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

  2023cited by this paper
• Ellagic acid inhibits proinflammatory intermediary manufacture by suppressing NF-κB/Akt, VEGF and activating Nrf-2/Caspase-3 signaling pathways in rat testicular damage: a new way for testicular damage cure and in silico approach

  2022cited by this paper
• Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment

  2022cited by this paper
• BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination

  2022cited by this paper
• Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.

  2022cited by this paper
• Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan

  2022cited by this paper
• Bidirectional regulation role of PARP-1 in high glucose-induced endothelial injury.

  2022cited by this paper
• Design, Synthesis and Molecular modeling study of certain Quinazolinone derivatives targeting Poly (ADP-ribose) polymerase 1 (PARP-1) enzyme as anti-breast cancer and radio-sensitizers

  2022cited by this paper
• Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.

  2022cited by this paper
• Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.

  2022cited by this paper
• PLK1 promotes cholesterol efflux and alleviates atherosclerosis by up-regulating ABCA1 and ABCG1 expression via the AMPK/PPARγ/LXRα pathway.

  2022cited by this paper
• Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone.

  2022cited by this paper
• Shedding light on the binding mechanism of kinase inhibitors BI-2536, Volasetib and Ro-3280 with their pharmacological target PLK1.

  2022cited by this paper
• hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors

  2021cited by this paper
• Fatty acid composition, enzyme inhibitory effect, antioxidant and anticancer activity of extract from Saponaria prostrata WILLD. subsp. anatolica HEDGE.

  2021cited by this paper
• Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer

  2021cited by this paper
• MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

  2020cited by this paper
• PARP and PARG inhibitors in cancer treatment.

  2020cited by this paper
• Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

  2020cited by this paper
• Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.

  2020cited by this paper
• Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy

  2020cited by this paper
• The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis

  2020cited by this paper
• Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition

  2020cited by this paper
• In-silico design and synthesis of N9-substituted β-Carbolines as PLK-1 inhibitors and their in-vitro/in-vivo tumor suppressing evaluation.

  2019cited by this paper
• Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.

  2019cited by this paper
• A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma

  2019cited by this paper
• Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

  2018cited by this paper
• Development and validation of a high‐performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells

  2018cited by this paper
• BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells

  2018cited by this paper
• Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.

  2018cited by this paper
• Ellagic acid impedes carbontetrachloride-induced liver damage in rats through suppression of NF-kB, Bcl-2 and regulating Nrf-2 and caspase pathway.

  2018cited by this paper
• Rational Design of a 310 -Helical PIP-Box Mimetic Targeting PCNA, the Human Sliding Clamp.

  2018cited by this paper
• Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells.

  2017cited by this paper
• Synthetic lethality and cancer

  2017cited by this paper
• PLK1, A Potential Target for Cancer Therapy

  2016cited by this paper
• Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.

  2016cited by this paper
• NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction

  2016cited by this paper
• Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.

  2015cited by this paper
• PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins

  2015cited by this paper
• BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.

  2015cited by this paper
• Regulation of DNA damage responses and cell cycle progression by hMOB2.

  2015cited by this paper
• β-Mangostin induces p53-dependent G2/M cell cycle arrest and apoptosis through ROS mediated mitochondrial pathway and NfkB suppression in MCF-7 cells

  2014cited by this paper
• Tracing the Evolution of the p53 Tetramerization Domain

  2014cited by this paper
• Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells

  2013cited by this paper
• Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck.

  2013cited by this paper
• In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer

  2012cited by this paper
• Specific recognition of phosphorylated tail of H2AX by the tandem BRCT domains of MCPH1 revealed by complex structure.

  2012cited by this paper
• Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Assessment of Apoptosis by Immunohistochemistry to Active Caspase-3, Active Caspase-7, or Cleaved PARP in Monolayer Cells and Spheroid and Subcutaneous Xenografts of Human Carcinoma

  2009cited by this paper
• AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

  2009cited by this paper
• AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

  2009cited by this paper
• Development of HER2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods

  2008cited by this paper
• Research Article: Selectivity‐determining Residues in Plk1

  2007cited by this paper
• p53 and its downstream proteins as molecular targets of cancer

  2006cited by this paper
• Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling

  2006cited by this paper
• BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.

  2002cited by this paper
• Structure of NF-κB p50 homodimer bound to a κB site

  1998cited by this paper
• Structure of NF-kappa B p50 homodimer bound to a kappa B site.

  1995cited by this paper

• Resveratrol potentiates chemotherapeutic efficacy of olaparib in MCF7 human breast cancer cells by inducing apoptosis.

  2026cites this paper